Skip to main content

Regulated information – inside information: Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and confirms FY guidance range

Written by Customer Service on . Posted in Public Companies.

Regulated information – inside information
Nazareth-De Pinte (Belgium)/Rotterdam (The Netherlands), 8 October 2026 – 7:00 AM CET

Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and confirms FY guidance range

Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 30 September 2026.

Key Highlights

  • Revenue of €281.3 million, up 23.2% (19.5% at CER1), supported by strong performance in EMEA, Latin America and Brands & Essentials (B&E) in North America–Pacific, together with contribution from acquisitions
  • Organic growth at CER of 3.4%, led by EMEA (6.5%), Latin America (9.7%) and B&E in North America–Pacific (26.1%)
  • Compounding Services in North America–Pacific was impacted by the temporary, industry-wide IV bag recall. The situation has now stabilized, and we expect volumes to transition to normalized levels through Q4
  • Completed the acquisition of Injeplast in Brazil; all previously announced acquisitions are now closed, with integration on track
  • FY 2026 revenue outlook confirmed to €1,125 – €1,150 million with an adj. EBITDA margin of 19.5% – 20.0%
  • Fagron will host its Capital Markets Day at the FSS facility in Wichita, Kansas, in October 2027

Rafael Padilla, CEO of Fagron:

“Our third quarter shows the strength of our diversified model. In EMEA, growth was led by Compounding Services, driven by new customer wins and rising underlying demand, while in Latin America, performance was supported by a successful Consulfarma fair and our acquisitions in Brazil added further momentum.

In North America–Pacific, Brands & Essentials delivered another strong quarter, while Compounding Services was held back by the industry-wide IV bag recall. Supply has now stabilized, and we expect volumes to recover progressively through the fourth quarter.

With Injeplast completed, all previously announced acquisitions are now closed and integrating well. Our M&A pipeline remains strong, with a clear focus on disciplined, value-accretive opportunities to strengthen our global leadership.

For 2026, we expect revenue of €1,125 – €1,150 million with an adj. EBITDA margin of 19.5% – 20.0%. We believe North America–Pacific has reached an inflection point. As IV bag volumes recover, maintaining our quality leadership, our expansion projects come on stream and our acquisitions contribute fully, we are well positioned for a strong 2027. Our mid-term objectives remain unchanged.”

1 Constant exchange rate

Webcast
Rafael Padilla (CEO) and Karin de Jong (CFO) will discuss the trading update in a webcast starting at 9.30 AM CET. Registration to the webcast is available via this link. The presentation for the call will be available to download from the Fagron website around 7.00 AM CET.

Further information
Ignacio Artola
Global Head of Investor Relations
Tel. +34 670385795
Ignacio.artola@fagron.com

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.